We’ve recently updated our valuation analysis.

Cannasouth Valuation

Is CBD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBD?

Other financial metrics that can be useful for relative valuation.

CBD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue17.4x
Enterprise Value/EBITDA-8.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CBD's PS Ratio compare to its peers?

The above table shows the PS ratio for CBD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average16.9x
RUA Rua Bioscience
BLT BLIS Technologies
AFT AFT Pharmaceuticals
A052670 Cheilbio
CBD Cannasouth

Price-To-Sales vs Peers: CBD is good value based on its Price-To-Sales Ratio (16.3x) compared to the peer average (16.9x).

Price to Earnings Ratio vs Industry

How does CBD's PE Ratio compare vs other companies in the Oceanian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a35.8%

Price-To-Sales vs Industry: CBD is expensive based on its Price-To-Sales Ratio (16.3x) compared to the Oceanic Pharmaceuticals industry average (7.4x)

Price to Sales Ratio vs Fair Ratio

What is CBD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CBD's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CBD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CBD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CBD's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies